A Double-Blind Multicenter Group Comparative Study of the Efficacy and Safety of Nedocromil Sodium in the Management of Asthma: Results (5)

Pulmonary Function
The changes in clinic and diary card pulmonary function data were consistent across the centers and the data were pooled for analysis. buy prednisone
As a percentage of baseline values, PEFR did not vary (0.2 to 0.9 percent) in either treatment group during the first two weeks (Fig 4). The most marked change was a 5 percent fall from the morning and evening baseline PEFRs in the placebo-treated patients during the period when SRTs were withdrawn, compared with a 1 percent fall in these values in the nedocromil sodium group; morning PEFR values were significantly (p = 0.01) in favor of nedocromil sodium. The differences between treatments were significant for both morning (p = 0.01) and evening (p = 0.03) PEFR for weeks 7 to 14, with placebo PEFRs falling by more than 6 percent compared with less than 2 percent in the nedocromil sodium group. Compared with the baseline, the difference between the treatment groups during weeks 7 to 14 increased by 165 percent and 85 percent, (morning and evening measurements respectively), despite the higher baseline values in the nedocromil sodium group.

Figure_4

Figure 4. Graph of daily diary card morning and evening peak expiratory flow rate (PEFR) (liters per minute) represented as mean values for each period of assessment. Closed circles indicate nedocromil sodium; open circles, placebo; solid line, morning; and dashed line, evening. Statistically significant between treatment differences as marked. The p-values are based on the nonparametric stratified randomization covariance analysis. Note suppressed zero on y-axis. Error bars indicate standard error of the mean.

Category: Pulmonary function

Tags: asthma, bronchodilator, nedocromil sodium, pulmonary function